GLP-1 receptor agonists for type 2 diabetes.
De Block
Christophe E M
CE
Antwerp University Hospital and University of Antwerp, Department of Diabetology and Endocrinology, Wilrijkstraat 10, 2650 Edegem, Antwerp, Belgium. christophe.deblock@ua.ac.be
Van Gaal
Luc F
LF
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D015337:Multicenter Studies as Topic; D010455:Peptides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide